ENDRA Life Sciences Q1 2025 Financial Results and Business Update

ENDRA Life Sciences Inc., a pioneer in Thermo-Acoustic Enhanced UltraSound (TAEUS®), has released its financial results for the first quarter of 2025, ending March 31, 2025. The company has also provided a comprehensive business update, highlighting significant strategic shifts and operational efficiencies.

Financial Highlights

For the first quarter of 2025, ENDRA reported a net loss of $1.0 million, a substantial improvement from the $2.8 million net loss in the same period last year. The company's cash burn was reduced to $1.2 million, down from $1.7 million in Q1 2024. Total operating expenses decreased nearly 50% to $1.5 million, reflecting aggressive cost-cutting measures. As of March 31, 2025, ENDRA had $2.1 million in cash and cash equivalents, with an additional $0.8 million raised post-quarter under its ATM facility.

Business and Operational Highlights

ENDRA has strategically pivoted to focus on the diagnosis and management of metabolic diseases, particularly steatotic liver disease (SLD). The company is developing a low-cost, point-of-care diagnostic device for liver fat detection, akin to a "blood pressure cuff" for the liver. This device aims to address the diagnostic gap in SLD, which affects over 2 billion people globally.

Under its new go-to-market strategy, ENDRA has identified four key customer segments: pharmaceutical companies and clinical research organizations, concierge medical practices, bariatric and endocrinology clinics, and primary care providers. The company is also redesigning its TAEUS Liver system to enhance usability, performance, and affordability, incorporating AI-powered enhancements and a compact design.

Strategic Initiatives and Corporate Developments

ENDRA has revised its regulatory strategy for the De Novo submission of its TAEUS Liver device to the FDA. The company plans to conduct a hypothesis-driven, statistically powered prospective clinical trial with approximately 250 subjects. Additionally, ENDRA is offering its TAEUS Liver device through a subscription model to accelerate adoption and market penetration.

Looking ahead, ENDRA plans to expand the utility of its TAEUS platform beyond liver fat measurement to include applications such as temperature monitoring during ablation therapies and vascular imaging. The company was also issued two new patents in China, bringing its total intellectual property portfolio to 84 patents.

Management's Perspective

Alexander Tokman, ENDRA’s CEO, emphasized the potential of TAEUS technology to transform the management of metabolic diseases by providing earlier detection and broader access to liver fat assessment. Tokman highlighted the significant healthcare costs associated with obesity and type 2 diabetes, underscoring the importance of ENDRA's innovative diagnostic solutions.

Future Outlook

ENDRA is focused on advancing its strategic initiatives, including the pivotal clinical trial for the TAEUS Liver device and expanding its market reach through a subscription-based model. The company aims to continue reducing operational costs while enhancing its product offerings and exploring new applications for its thermoacoustic technology.

SEC Filing: ENDRA Life Sciences Inc. [ NDRA ] - 8-K - May. 15, 2025